Alliance for Pharmacy Compounding

11/21/2025

Big news! NY governor Kathy Hochul just signed a bill allowing pharmacy technicians to perform compounding under supervision of a pharmacist. It’s good to see years of advocacy efforts by NY compounders, PSSNY, and others finally come to fruition.

Read the new law: https://bit.ly/4o449Rr

11/21/2025

APC in Inside Health Policy. APC’s demand that FDA reverse course on its ban of DTE in compounding has made it mainstream — Inside Health Policy not only covered our letter to the agency, it did so in one of the best, most comprehensive and accurate stories we’ve seen on the issue. Check out, “Amid CDER Chaos, Compounders Want Reversal Of Tidmarsh’s DTE Move”. https://bit.ly/48fqyW9

So good, so good, so good. Our New England regional meeting was a cozy affair befitting the location and the season. Attendees had a great evening with cocktails, dinner, networking, a policy update, and more. A big thanks to Colanar for sponsoring it!

Maybe experts don’t need committees? FDA commish Marty Makary took a shot at the agency’s advisory committees, calling them “bureaucratic, long and often conflicted, and very expensive.” He was talking specifically about why the FDA didn’t convene a panel of outside advisers before recommending the removal of the boxed warning on hormone replacement therapy, but it could signal another shift in how the agency uses its experts to make policy decisions.

11/21/2025

"Recently DTE has come under attack, and this is not acceptable. It is not acceptable because we serve clients who are in dire need of specialty compounded medication '

The FDA is moving to reclassify desiccated thyroid extract (DTE) as a biologic next August — a change that would end compounding and remove existing commercial DTE products from the market. For many patients, that means losing access to the only thyroid therapy that truly supports their health.

APC is actively working to stop this, but patient and practitioner voices are essential. If DTE is part of your care or your practice, now is the time to speak up: https://bit.ly/4oPHfOS

Your input can help preserve access for those who depend on it.

11/20/2025

FDA pulls HRT boxed warning — and that’s big news.

The FDA has officially removed the long-criticized boxed warning from menopausal HRT products — a reversal the agency itself called “historic.” The warning, based on flawed early-2000s data, overstated risks of heart disease, breast cancer, and dementia and fueled decades of unnecessary fear.

Why it matters for compounding: Commissioner Marty Makary’s comments suggest a shift toward a more evidence-driven, patient-centered approach — and potentially less reliance on the discredited 2020 NASEM report when evaluating compounded hormones.

As Makary put it, “HRT has saved marriages, rescued women from depression, [and] prevented children from going without a mother.” A promising sign of better policy ahead.

11/20/2025

Compounding isn’t an emergency measure — it’s everyday medicine.

A recent Colorado Politics opinion piece by respected outsourcing facility leaders Joe Bagan and Paul Granberry reinforces a truth our industry has known all along:

Patients rely on compounded medications every day — not only during drug shortages.

Compounding fills real, persistent gaps in healthcare:
✅ When a patient needs a different dose
✅ When allergies require alternative ingredients
✅ When hospitals depend on ready-to-use sterile medications
✅ When no commercial product fits the clinical need

Facilities like STAQ Pharma — a cGMP-compliant, hospital-trusted 503B outsourcing facility — play a critical role in ensuring reliable, high-quality access to compounded therapies.

If we want patients to receive the therapies they need, policymakers, practitioners, and the public must understand this simple reality:

Compounding is essential. Every day.

11/19/2025

🚨TOMORROW 🚨

There’s a good chance you want to grow or at least improve your pharmacy. That can mean different things to different people, but the one thing you all need is data. You can’t say you’ve improving if you don’t know where you’re starting from (or what exactly “improving” means).

That’s why we’ve got our latest webinar in partnership with LP3: “Metrics that Motivate.” It’s all about how to create the right indicators — key performance indicators, or KPIs — so you’ve got real, actionable data points to set goals and measure performance. And that’s across the board, from obvious financial indicators to how well your deliveries are meeting (or exceeding) expectations.

It’s just $55 for APC pharmacist members ($75 for non-members) or $25 for pharmacy technicians and students.

Register today! https://bit.ly/4pjZNXw

11/19/2025

🚨 Don't miss Informa Connect's Compounding Pharmacy Compliance Year-End Update. Join us December 9-10 in Philadelphia for critical GLP-1 regulatory updates and compliance strategies. Our CEO Scott Brunner and Chief Advocacy Officer Tenille Scott will be sharing essential insights during the program. This is the must-attend follow-up to June's summit, and APC members save 15%!

View the full agenda: https://bit.ly/43D6onz

11/18/2025

More myth-busting from APC — now in the DC Journal.

Our own Scott Brunner's new op-ed, “Compounded GLP-1s, a Healthcare Lifeline, Not a Scandal,” takes direct aim at the misinformation drugmakers keep spreading about compounding. It’s a clear, point-by-point debunking of the biggest myths — from exaggerated safety claims to accusations about ingredient quality, legality, and personalization.

Scott also reminds readers that the courts aren’t buying those narratives either: “Courts see what’s really happening — pharmacists and prescribers filling a gap in patient access within the clear bounds of law.”

If you’ve been dealing with these “misrepresentations” yourself, this op-ed is required reading:

Courts appear to be affirming what pharmacists have long known: compounding GLP-1 medications for patients who can’t access the brand-name versions is a

11/17/2025

APC to BOPs: Don’t fall for it

Drugmakers continue spreading misinformation about compounded GLP-1s — and now they’re bringing it straight to state boards of pharmacy. So this week, APC sent a memo to every BOP in the country, laying out the facts and calling out the misleading claims point-by-point.

Boards are smart enough to see through it, but we wanted to give them clear, documented information — and highlight just how far some manufacturers are going to create confusion.

“Accurate information is essential for maintaining uniform regulatory standards and protecting public health,” we wrote. And throwing a bit of passive shade, we concluded, “We respectfully encourage boards to evaluate manufacturer presentations with the same evidentiary standards applied to all stakeholders.”

Read the letter we sent: https://bit.ly/49lv5bT

11/14/2025

🚨New Rotation Student!🚨

Akaellah Rice joins APC as a P4 student pharmacist at the University of South Carolina. She is interested in learning about nontraditional roles in pharmacy and hopes to gain a deeper understanding of compounding regulation and advocacy.

"Through this rotation, I hope to broaden my understanding on how pharmacists make an impact beyond direct patient care and help move the profession forward through advocacy and policy."

Welcome to APC, Akaellah! 👏

11/14/2025

This sounds familiar. For more than three years, compounding pharmacies have provided safe, affordable GLP-1 drugs for Americans, Scott Brunner wrote on LinkedIn. And now it looks like drugmakers have made a deal with the White House to offer their weight-loss drugs for just $149 per month in exchange for having them covered by Medicaid and Medicare. There’s a direct line from one to the other, Scott points out. “You’re welcome.”

Potential API confusion in Rhode Island. The Rhode Island Board of Pharmacy proposed updating their compounding regulations to adopt the newer USP Chapters and .That’s good, but when we looked at the details, there appear to be issues in the API selection criteria. APC will be submitting comments to the board once we fully evaluate those proposed changes.